Hickford Elizabeth S, Dejager Lien, Yuill Daisy, Kotian Apoorva, Shankar Sucharita, Staelens Ludovicus, Ulrichts Hans, Lewis Sion, Louber Jade, Williams Amanda, Le Provost Gabrielle S, Cutler Paul
Translational Biomarkers & Bioanalysis, Development Sciences, UCB Biopharma UK, Bath Road, Slough, SL1 3WE, UK.
Precision Medicine & Biomarkers, Translational Medicine, UCB Pharma, Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium.
Bioanalysis. 2023 Jul;15(13):757-771. doi: 10.4155/bio-2023-0110. Epub 2023 Aug 1.
It is widely acknowledged by the bioanalytical and biomarker community that biomarker assay validations should be fit-for-purpose depending on the context of use. The challenge is how to consistently apply these principles in teams responsible for measuring a disparate array of biomarkers, often on multiple analytical platforms, at various stages of the drug discovery and development pipeline and across diverse biology focus areas. To drive consistency, while maintaining the necessary flexibility to allow validations to be driven by scientific rationale and taking into consideration the context of use and associated biological and (pre)analytical factors, a framework applicable across biomarker assays was developed. Herein the authors share their perspective to engage in the ongoing conversation around fit-for-purpose biomarker assay validation.
生物分析和生物标志物领域普遍认为,生物标志物分析验证应根据使用背景进行量身定制。挑战在于如何在负责测量一系列不同生物标志物的团队中始终如一地应用这些原则,这些团队通常在药物发现和开发管道的各个阶段,在多个分析平台上,以及跨不同的生物学重点领域开展工作。为了推动一致性,同时保持必要的灵活性,使验证能够由科学原理驱动,并考虑到使用背景以及相关的生物学和(预)分析因素,开发了一个适用于所有生物标志物分析的框架。在此,作者分享他们的观点,以参与围绕量身定制的生物标志物分析验证的持续讨论。